13F Holdings
中文EN

PBM PSYENCE BIOMEDICAL LTD. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1985062 · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY102.0%
TTM EPS YoY100.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA24.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets8.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income-3.69x
Accruals ratio112.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-03-31FY2024*2024-03-31FY2023*2023-03-31
Income statement
Revenue———
R&D expense$342,168$954,593$1.61M
SG&A expense$1.21M$557,904$366,435
Interest expense$9,270$52,941—
Pretax income-$3.66M-$2.75M-$3.23M
Net income$1.01M-$51.16M-$3.21M
EPS (basic)5.24-4,674.25-394.06
EPS (diluted)5.24-4,674.25-394.06
Weighted avg. shares (diluted)193,04310,9038,365
Balance sheet
Cash & equivalents$6.14M$733,188$1.33M
Current assets$6.56M$1.13M$1.59M
PP&E, netmay include right-of-use assets (IFRS)$11,096$5,487—
Total assets$7.32M$1.13M$1.59M
Total liabilities$594,366$12.10M$1.79M
Shareholders' equity$6.72M-$10.97M-$200,445
Shares outstanding—178,5420
Cash flow statement
Operating cash flow-$3.73M-$2.95M-$1.59M
Capital expenditure$9,877$5,727—
Free cash flow-$3.74M-$2.95M—
Investing cash flow-$16,230-$5,727—
Financing cash flow$9.15M$2.35M$1.17M
Stock-based compensation—$317,882$221,287

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.